## Dan Zhao

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/989095/publications.pdf

Version: 2024-02-01

304743 276875 1,767 49 22 41 citations h-index g-index papers 54 54 54 3340 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	A Preoperative Nomogram for Predicting Chemoresistance to Neoadjuvant Chemotherapy in Patients with Locally Advanced Cervical Squamous Carcinoma Treated with Radical Hysterectomy. Cancer Research and Treatment, 2021, 53, 233-242.	3.0	3
2	Molecular and Clinical Features of Hospital Admissions in Patients with Thoracic Malignancies on Immune Checkpoint Inhibitors. Cancers, 2021, 13, 2653.	3.7	2
3	Construction of the cervical cancer common terminology for promoting semantic interoperability and utilization of Chinese clinical data. BMC Medical Informatics and Decision Making, 2021, 21, 309.	3.0	5
4	Clinical Outcomes in Early Cervical Cancer Patients Treated with Nerve Plane–sparing Laparoscopic Radical Hysterectomy. Journal of Minimally Invasive Gynecology, 2020, 27, 687-696.	0.6	6
5	Refractive error outcomes after intravitreal ranibizumab for retinopathy of prematurity. Australasian journal of optometry, The, 2020, 103, 495-500.	1.3	1
6	Ethnic disparities in demographic, clinicopathologic and biological behaviours and prognosis of gastric cancer in northwest China. Cancer Medicine, 2020, 9, 9353-9364.	2.8	2
7	Association of molecular characteristics with survival in advanced non-small cell lung cancer patients treated with checkpoint inhibitors. Lung Cancer, 2020, 146, 174-181.	2.0	8
8	International consensus on natural orifice specimen extraction surgery (NOSES) for gastric cancer (2019). Gastroenterology Report, 2020, 8, 5-10.	1.3	30
9	Characteristics and treatment results of recurrence in adult-type granulosa cell tumor of ovary. Journal of Ovarian Research, 2020, 13, 19.	3.0	17
10	Association Between Spatial Heterogeneity Within Nonmetastatic Gastroesophageal Adenocarcinomas and Survival. JAMA Network Open, 2020, 3, e203652.	5.9	19
11	Alterations in STK11 to limit response to immune checkpoint inhibitors in lung cancer Journal of Clinical Oncology, 2020, 38, e21503-e21503.	1.6	0
12	Evaluation of immune-related adverse events in patients treated with sequential immunotherapy and tyrosine kinase inhibitor treatment in non-small cell lung cancer Journal of Clinical Oncology, 2020, 38, e21562-e21562.	1.6	0
13	Separate lateral parametrial lymph node dissection improves detection rate of parametrial lymph node metastasis in early-stage cervical cancer: 10-year clinical evaluation in a single center in China. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research. 2020. 32. 804-814.	2.2	1
14	Targeted Therapies in Non-small-Cell Lung Cancer. Cancer Treatment and Research, 2019, 178, 3-43.	0.5	16
15	Progress and challenges in HER2-positive gastroesophageal adenocarcinoma. Journal of Hematology and Oncology, 2019, 12, 50.	17.0	44
16	Outcomes of fertility-sparing surgery in ovarian juvenile granulosa cell tumor. International Journal of Gynecological Cancer, 2019, 29, 787-791.	2.5	14
17	Comparison Study of Laparoscopic Sentinel Lymph Node Mapping in Endometrial Carcinoma Using Carbon Nanoparticles and Lymphatic Pathway Verification. Journal of Minimally Invasive Gynecology, 2019, 26, 1125-1132.	0.6	24
18	Molecular and clinical features of hospital admissions and immunotherapy related adverse events of immune checkpoint inhibitors in thoracic malignancies Journal of Clinical Oncology, 2019, 37, e18192-e18192.	1.6	0

#	Article	lF	CITATIONS
19	Updates on Immunotherapy for the Treatment of Skin Cancer. Current Dermatology Reports, 2018, 7, 311-320.	2.1	2
20	GDF15 predict platinum response during first-line chemotherapy and can act as a complementary diagnostic serum biomarker with CA125 in epithelial ovarian cancer. BMC Cancer, 2018, 18, 328.	2.6	29
21	Limited energy parametrial resection/dissection during modified laparoscopic nerve-sparing radical hysterectomy. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2018, 30, 647-655.	2.2	4
22	Prognostic evaluation of postoperative adjuvant therapy for operable cervical cancer: 10 years' experience of National Cancer Center in China. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2017, 29, 510-520.	2.2	22
23	Circulating MIC-1/GDF15 is a complementary screening biomarker with CEA and correlates with liver metastasis and poor survival in colorectal cancer. Oncotarget, 2017, 8, 24892-24901.	1.8	39
24	Cancer stem cell-related gene expression as a potential biomarker of response for first-in-class imipridone ONC201 in solid tumors. PLoS ONE, 2017, 12, e0180541.	2.5	28
25	A novel serum based biomarker panel has complementary ability to preclude presence of early lung cancer for low dose CT (LDCT). Oncotarget, 2017, 8, 45345-45355.	1.8	8
26	ATPS-852-HYDROXYGLUTARATE DEPLETION IS NOT SUFFICIENT TO INHIBIT GROWTH OF SEVERAL PROGRESSIVE IDH1 MUTANT SOLID CANCER TYPES. Neuro-Oncology, 2015, 17, v37.2-v37.	1.2	2
27	Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion. Cancer Cell, 2015, 28, 773-784.	16.8	327
28	Role of Neoadjuvant Chemotherapy in the Management of Advanced Ovarian Cancer. Asian Pacific Journal of Cancer Prevention, 2015, 16, 2369-2373.	1.2	5
29	Targetable Signaling Pathway Mutations Are Associated with Malignant Phenotype in <i>IDH</i> -Mutant Gliomas. Clinical Cancer Research, 2014, 20, 2898-2909.	7.0	146
30	ONC201 Depletes Cancer Stem Cells in Refractory Cancer Patient Samples. Blood, 2014, 124, 5219-5219.	1.4	2
31	Targetable signaling pathway mutations and progression of <i>IDH</i> -mutant glioma Journal of Clinical Oncology, 2014, 32, 2061-2061.	1.6	0
32	ONC201, a small molecule Foxo3a activator, activity against patient-derived glioblastoma tumor-initiating cells Journal of Clinical Oncology, 2014, 32, e13022-e13022.	1.6	0
33	MicroRNAâ€1322 regulates <i>ECRG2</i> allele specifically and acts as a potential biomarker in patients with esophageal squamous cell carcinoma. Molecular Carcinogenesis, 2013, 52, 581-590.	2.7	46
34	The oncogenetic role of microRNA-31 as a potential biomarker in oesophageal squamous cell carcinoma. Clinical Science, 2011, 121, 437-447.	4.3	126
35	Functional evaluation of missense variations in the human MAD1L1 and MAD2L1 genes and their impact on susceptibility to lung cancer. Journal of Medical Genetics, 2010, 47, 616-622.	3.2	42
36	Functional Role of <i>\$100A14</i> Genetic Variants and Their Association with Esophageal Squamous Cell Carcinoma. Cancer Research, 2009, 69, 3451-3457.	0.9	38

#	Article	IF	Citations
37	Genetic polymorphism in chemokine CCL22 and susceptibility to ⟨i⟩Helicobacter pylori⟨ i⟩ infectionâ€related gastric carcinoma. Cancer, 2009, 115, 2430-2437.	4.1	15
38	<i>Cyclooxygenaseâ€2</i> Gly587Arg variant is associated with differential enzymatic activity and risk of esophageal squamousâ€eell carcinoma. Molecular Carcinogenesis, 2009, 48, 934-941.	2.7	11
39	Interaction of Cyclooxygenase-2 Variants and Smoking in Pancreatic Cancer: A Possible Role of Nucleophosmin. Gastroenterology, 2009, 136, 1659-1668.	1.3	50
40	Association of the variable number of tandem repeats polymorphism in the promoter region of the SMYD3 gene with risk of esophageal squamous cell carcinoma in relation to tobacco smoking. Cancer Science, 2008, 99, 787-791.	3.9	23
41	Functional Variants in Cell Death Pathway Genes and Risk of Pancreatic Cancer. Clinical Cancer Research, 2008, 14, 3230-3236.	7.0	82
42	Characterization of Functional Excision Repair Cross-Complementation Group 1 Variants and Their Association with Lung Cancer Risk and Prognosis. Clinical Cancer Research, 2008, 14, 2878-2886.	7.0	52
43	Interaction of P53 Arg72Pro and MDM2 T309G polymorphisms and their associations with risk of gastric cardia cancer. Carcinogenesis, 2007, 28, 1996-2001.	2.8	68
44	Associations of functional polymorphisms in cyclooxygenase-2 and platelet 12-lipoxygenase with risk of occurrence and advanced disease status of colorectal cancer. Carcinogenesis, 2007, 28, 1197-1201.	2.8	89
45	Role of <i>CD14</i> Promoter Polymorphisms in <i>Helicobacter pylori</i> Infection–Related Gastric Carcinoma. Clinical Cancer Research, 2007, 13, 2362-2368.	7.0	42
46	Platelet 12-lipoxygenase Arg261Gln polymorphism: functional characterization and association with risk of esophageal squamous cell carcinoma in combination with COX-2 polymorphisms. Pharmacogenetics and Genomics, 2007, 17, 197-205.	1.5	35
47	Functional polymorphisms in FAS and FASL contribute to increased apoptosis of tumor infiltration lymphocytes and risk of breast cancer. Carcinogenesis, 2006, 28, 1067-1073.	2.8	89
48	Haplotypes in Matrix Metalloproteinase Gene Cluster on Chromosome 11q22 Contribute to the Risk of Lung Cancer Development and Progression. Clinical Cancer Research, 2006, 12, 7009-7017.	7.0	39
49	FASL –844C polymorphism is associated with increased activation-induced T cell death and risk of cervical cancer. Journal of Experimental Medicine, 2005, 202, 967-974.	8.5	104